Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS)

Launched by UNIVERSITY OF MANITOBA · Aug 2, 2023

Keywords

ClinConnect Summary

The MiMICSS trial is studying a new way to monitor how well the tiny blood vessels are working in critically ill patients, specifically those who are experiencing severe conditions like sepsis and shock. Researchers want to see if a special device that uses near-infrared light (called NIRS) can help track this important aspect of health. The study is currently looking for participants who are 65 years or older, are receiving mechanical ventilation in the ICU, and meet certain health criteria.

If you or a loved one is eligible and decides to participate, you can expect to have the NIRS device applied while you are in the hospital. This device is non-invasive, meaning it doesn’t require any surgery or needles, and it simply monitors blood flow in the small vessels. It’s important to note that not everyone can join the study; for example, those with a very high body weight or certain medical conditions may be excluded. The goal of this trial is to better understand how to care for patients in critical condition, potentially leading to improved care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to ICU
• • Receiving invasive mechanical ventilation
• Exclusion Criteria:
• • Body Mass Index \>40
• • More than 24 hours has elapsed since ICU admission
• • Death is deemed to be imminent and inevitable during the next 24 hours
• • Known allergy to the textile components of the device
• • Significant clinical jaundice, ecchymosis
• • COVID positive microbiological result
• • The treating clinician believes that participation in the domain would not be in the best interests of the patient
• • Consent declined from patient or authorized third party